Skip to main content
Premium Trial:

Request an Annual Quote

Lynx and Solexa Tie the Knot; First Gene-Analysis Product Planned for End of Year

NEW YORK, March 7 (GenomeWeb News) - UK-based Solexa and Lynx Therapeutics of Hayward, Calif., have completed their previously announced merger, the companies said today.

 

The combined company, which will be called Solexa, is incorporated in Delawareand will start trading today on the Nasdaq SmallCap Market under the symbol SLXA. The company's UKoperation has become a wholly owned subsidiary, the firms said.

 

Solexa said it plans to launch its first product, a gene-analysis platform based on sequencing-by-synthesis and micorarrays, by the end of the year. Initially, the company will focus on the research market.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.